Brief: Kairos Pharma To Present Positive Safety And Efficacy Data From Phase 2 Prostate Cancer Trial At Esmo 2025
07/10/2025 13:12
Oct 7 (Reuters) - Kairos Pharma Ltd KAPA.A: KAIROS PHARMA TO PRESENT POSITIVE SAFETY AND EFFICACY DATA FROM PHASE 2 PROSTATE CANCER TRIAL AT ESMO 2025 Source text: ID:nBw7f18xGa Further company coverage: KAPA.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kairos Pharma
See all newsBrief: Kairos Pharma Announces Signing Of Binding Strategic Asset Acquisition Of Exclusive Worldwide Rights To Cl-273 From Orbimed And Torrey Pines Investment-Backed Celyn Therapeutics
Brief: Kairos Pharma Announces Signing Of Term Sheet For Strategic Asset Acquisition
Brief: Kairos Pharma To Present Positive Safety And Efficacy Data From Phase 2 Prostate Cancer Trial At Esmo 2025
Brief: Kairos Pharma Reports Positive Interim Phase 2 Data For ENV105 In Advanced Prostate Cancer, PFS Over One Year
Brief: Kairos Pharma Announces Virtual KOL Event To Provide Perspectives On ENV105 Interim Efficacy Results In Advanced Prostate Cancer